11.00USD+0.82%Mkt Cap: 629.87M USDP/E: —Last update: 2026-05-22
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, a…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap629.87M USD
Enterprise Value412.07M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-59.85M USD
Revenue/Share—
Last Price11.00 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees28
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-9.72
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B3.52
EPS (TTM)-0.77
EPS (Forward)-1.12
52W Range
1.16087% of range12.48
52W High12.48 USD
52W Low1.160 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-37.30%
ROA-35.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-54.36M USD
CapEx (TTM)186.00K USD
FCF Margin—
FCF Yield-5.44%
Net Debt-109.08M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio27.86
Quick Ratio26.91
Book Value/Sh3.100 USD
Cash/Share2.294 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)19.77 USD
Target Range15.00 USD – 26.00 USD
# Analysts13
Ownership
Shares Out.57.26M
Float28.06M
Insiders0.37%
Institutions66.46%
Short Interest
Short Ratio2.6d
Short % Float4.38%
Short % Out.3.10%
Shares Short1.78M
Short (prev mo.)1.78M
Technical
SMA 508.716 (+26.2%)
SMA 2004.641 (+137.0%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)843.86K
Avg Vol (10d)661.72K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—